Literature DB >> 3922640

Beta-2-microglobulin excretion: an indicator of long term nephrotoxicity during cis-platinum treatment?

P G Sørensen, M H Nissen, S Groth, M Rørth.   

Abstract

To evaluate the value of beta-2-microglobulin as an indicator of acute and long-term cis-platinum-induced nephrotoxicity, 51Cr-EDTA clearance and serum concentration and urinary excretion of beta-2-microglobulin were measured in 18 patients treated with a regimen including cis-platinum. Before treatment all values were within the normal range. During treatment 51Cr-EDTA clearance decreased from 108 to 90 ml/min/1.73 m2 (P less than 0.02). The decrease was irreversible, while a transient 2 to 5-fold increase in beta-2-microglobulin excretion in the urine was seen during treatment. Serum beta-2-microglobulin remained unchanged. The decrease in 51Cr-EDTA clearance was not correlated to either the peak increase in the beta-2-microglobulin excretion or to the time of occurrence of the peak (R = 0.3). Thus, it is not possible to predict the long-term nephrotoxicity of cis-platinum by measuring the beta-2-microglobulin excretion during treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3922640     DOI: 10.1007/bf00258126

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

1.  Platinum nephrotoxicity.

Authors:  W T Hardaker; R A Stone; R McCoy
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

Review 2.  Immunochemical studies of human beta 2-microglobulin. A review of recent methodological progress and clinical applications.

Authors:  T Plesner
Journal:  Allergy       Date:  1980-12       Impact factor: 13.146

3.  The leakage of plasma albumin across small vessel walls during bleomycin treatment.

Authors:  P G Sørensen; S Groth; N Rossing
Journal:  Eur J Cancer Clin Oncol       Date:  1983-01

4.  Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma.

Authors:  S Meijer; D T Sleijfer; N H Mulder; W J Sluiter; J Marrink; H S Koops; T M Brouwers; J Oldhoff; G K van der Hem; E Mandema
Journal:  Cancer       Date:  1983-06-01       Impact factor: 6.860

5.  51Cr-EDTA clearance determined by one plasma sample.

Authors:  S Groth; M Aasted
Journal:  Clin Physiol       Date:  1981-08

Review 6.  Cisplatin (cis-diamminedichloroplatinum II).

Authors:  A W Prestayko; J C D'Aoust; B F Issell; S T Crooke
Journal:  Cancer Treat Rev       Date:  1979-03       Impact factor: 12.111

Review 7.  Beta-2-microglobulin review: its relevance in clinical oncology.

Authors:  E H Cooper; T Plesner
Journal:  Med Pediatr Oncol       Date:  1980

8.  Comparison of methods of evaluating nephrotoxicity of cis-platinum.

Authors:  B R Jones; R B Bhalla; J Mladek; R N Kaleya; R J Gralla; N W Alcock; M K Schwartz; C W Young; M M Reidenberg
Journal:  Clin Pharmacol Ther       Date:  1980-04       Impact factor: 6.875

9.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

10.  Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man.

Authors:  M Dentino; F C Luft; M N Yum; S D Williams; L H Einhorn
Journal:  Cancer       Date:  1978-04       Impact factor: 6.860

View more
  9 in total

Review 1.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  Biomarkers of Drug-Induced Kidney Toxicity.

Authors:  Benjamin R Griffin; Sarah Faubel; Charles L Edelstein
Journal:  Ther Drug Monit       Date:  2019-04       Impact factor: 3.681

3.  Acute and long-term nephrotoxicity of cis-platinum in man.

Authors:  S Groth; H Nielsen; J B Sørensen; A B Christensen; A G Pedersen; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 4.  Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy.

Authors:  Blessy George; Melanie S Joy; Lauren M Aleksunes
Journal:  Exp Biol Med (Maywood)       Date:  2017-12-12

5.  Linking mechanistic and behavioral responses to sublethal esfenvalerate exposure in the endangered delta smelt; Hypomesus transpacificus (Fam. Osmeridae).

Authors:  Richard E Connon; Juergen Geist; Janice Pfeiff; Alexander V Loguinov; Leandro S D'Abronzo; Henri Wintz; Christopher D Vulpe; Inge Werner
Journal:  BMC Genomics       Date:  2009-12-15       Impact factor: 3.969

6.  Urinary beta 2-microglobulin: early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide.

Authors:  C de Gislain; M Dumas; P d'Athis; J L Lautissier; A Escousse; J Guerrin
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.

Authors:  G Daugaard; N Rossing; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  Cumulative renal tubular damage associated with cisplatin nephrotoxicity.

Authors:  M P Goren; R K Wright; M E Horowitz
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Glomerular hyperfiltration and β-2 microglobulin as biomarkers of incipient renal dysfunction in cancer survivors.

Authors:  Fernanda R Tibúrcio; Karla E de S Rodrigues; André R Belisário; Ana Cristina Simões-E-Silva
Journal:  Future Sci OA       Date:  2018-08-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.